Please use this identifier to cite or link to this item:
Title: Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythm
Author: Formiga Pérez, Francesc
Chivite, David
Nuñez, Julio
Moreno García, Ma. Carmen
Manzano, Luis
Arévalo-Lorido, José Carlos
Cerqueiro, Jose Manuel
García Campos, Álvaro
Trullàs, Joan Carles
Montero Pérez-Barquero, Manuel
Keywords: Angiotensines
Insuficiència cardíaca
Heart failure
Issue Date: 1-Oct-2022
Publisher: Elsevier España
Abstract: Introduction: Beta-adrenergic receptor blockers (beta-blockers) are frequently used for patients with heart failure (HF) with preserved ejection fraction (HFpEF), although evidence-based recommendations for this indication are still lacking. Our goal was to assess which clinical factors are associated with the prescription of beta-blockers in patients discharged after an episode of HFpEF decompensation, and the clinical outcomes of these patients. Methods: We assessed 1078 patients with HFpEF and in sinus rhythm who had experienced an acute HF episode to explore whether prescription of beta-blockers on discharge was associated with one-year all-cause mortality or the composite endpoint of one-year all-cause death or HF readmission. We also examined the clinical factors associated with beta-blocker discharge prescription for such patients. Results: At discharge, 531 (49.3%) patients were on beta-blocker therapy. Patients on beta-blockers more often had a prior diagnosis of hypertension and more comorbidity (including ischemic heart disease) and a better functional status, but less often a prior diagnosis of chronic obstructive pulmonary disease. These patients had a lower heart rate on admission and more often used angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors and loop diuretics. One year after the index admission, 161 patients (15%) had died and 314 (29%) had experienced the composite endpoint. After multivariate adjustment, beta-blocker prescription was not associated with either all-cause mortality (HR=0.83 [95% CI 0.61-1.13]; p=0.236) or the composite endpoint (HR=0.98 [95% CI 0.79-1.23]; p=0.882). Conclusion: In patients with HFpEF in sinus rhythm, beta-blocker use was not related to one-year mortality or mortality plus HF readmission.
Note: Reproducció del document publicat a:
It is part of: Revista Portuguesa de Cardiologia, 2022, vol. 41, num. 10, p. 853-861
Related resource:
ISSN: 0870-2551
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
725589.pdf737.67 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons